Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
63 Leser
Artikel bewerten:
(0)

FUJIFILM's Synapse Cardiovascular 4.0.8 Featured at ACC

CHICAGO, March 24, 2012 /PRNewswire/ --Today at the 61st annual American College of Cardiology (ACC) Summit in Chicago, Ill., FUJIFILM Medical Systems U.S.A., Inc. introduced Synapse® Cardiovascular 4.0.8, the latest version of their web based solution for cardiovascular imaging. Synapse Cardiovascular 4.0.8 allows cardiology departments to have one-click access to review images and a shortened reporting process, freeing staff to spend critical time on patient care.

The image recall and playback speed of Synapse Cardiovascular 4.0.8 is greatly increased and made possible by incorporating quad-core processors, gigabyte (GB) level RAM, and GB speed networks.These enhancements provide greater capability to handle large image sets, enabling increased image recall and playback speeds by up to 100%.

Other enhancements to Synapse Cardiovascular 4.0.8 include:

  • Integration with Microsoft Active Directory
  • Ability to deploy application with Citrix XenApp and Citrix Desktop
  • Ability to use Dragon voice recognition to complete patient report comments
  • Direct integration with Parks Flo Lab physiologic monitoring systems

"Busy cardiology departments need solutions that will improve workflow and allow clinical efficiencies," says Jim Morgan, Fujifilm's Vice President of Medical Informatics. "The speed and performance enhancements of Synapse Cardiovascular 4.0.8 represent Fujifilm's continued commitment to listening to the needs of our customers and incorporate improvements that allow them to perform their job more efficiently.This improved workflow ultimately allows them to concentrate more on the patient and improve overall patient outcomes."

For more information on Synapse Cardiovascular 4.0.8 or for a product demonstration, visit FUJIFILM Medical Systems U.S.A., Inc., March 24th-26th at ACC booth #19053.

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women's health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc., supplies high quality, technologically advanced, FUJINON brand endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information visitwww.fujimed.comandwww.fujinonendoscopy.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. The company was among the top 16 companies around the world granted U.S. patents in 2010, and in the year ended March 31, 2011, had global revenues of $25.8 billion*. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visitwww.fujifilmholdings.com.

* At an exchange rate of 86 yen to the dollar.

© 2012 FUJIFILM Medical Systems U.S.A., Inc.

SOURCE FUJIFILM Medical Systems U.S.A., Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.